Effect of chlormadinone acetate-pellet implantation on the volume of prostate, peripheral blood levels of sex hormones and semen quality in the dog.
Chlormadinone acetate (GS implant, CMA) pellet, a synthetic luteal hormone preparation, was subcutaneously implanted at 5, 10 and 20 mg/kg in four normal male dogs ranging in age from 3 to 10 years to determine the changes in the prostatic volume, peripheral plasma levels of sex hormones and semen quality. The plasma levels of CMA, LH, testosterone (T) and 5 alpha-dihydrotestosterone (DHT) were measured by radioimmunoassay. The prostatic volume was measured by computed tomography. The semen was collected by digital manipulation. The pellet was removed 26 weeks after implantation. The effects of CMA pellet implantation were examined during implantation and until 22 weeks after removal. The prostatic volume was reduced to 61 +/- 3 (mean +/- S.E., n = 4), 52 +/- 5 (n = 4) and 53 +/- 9 (n = 4)% of the preimplantation volumes in the 5, 10 and 20 mg/kg groups, respectively. The plasma CMA levels in the 10 mg/kg and 20 mg/kg groups peaked at 2 weeks, but were gradually decreased. At 22 weeks after removal of the pellet, the prostatic volume returned to 74-85% of the preimplantation volumes. The plasma LH levels tended to increase after implantation in all groups. The plasma T and DHT levels were slightly decreased in all groups. In the 10 and 20 mg/kg groups, the number of sperm and motility sperm was reduced, and the rate of abnormal sperm increased.(ABSTRACT TRUNCATED AT 250 WORDS)
Shimizu
M
M
Department of Reproduction, Nippon Veterinary and Animal Science University, Tokyo, Japan.
Tsutsui
T
T
Kawakami
E
E
Hori
T
T
Fujita
M
M
Orima
H
H
Ogasa
A
A
D000375:Aging / Q000502:physiology; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D013196:Dihydrotestosterone / Q000097:blood*; D004283:Dog Diseases; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D011467:Prostate / Q000033:anatomy & histology* / Q000187:drug effects / Q000254:growth & development; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000662:veterinary; D012661:Semen / Q000187:drug effects / Q000502:physiology*; D013081:Sperm Motility / Q000187:drug effects; D013094:Spermatozoa / Q000002:abnormalities / Q000187:drug effects; D013739:Testosterone / Q000097:blood*; D013997:Time Factors
D004343:Drug Implants; D045167:Progesterone Congeners; D013196:Dihydrotestosterone; D002715:Chlormadinone Acetate; D013739:Testosterone; D007986:Luteinizing Hormone